Antitumor activity of tilorone hydrochloride on a transplantable rat adenocarcinoma.
Tilorone HCL, administered in drinking water, retarded and slowed significantly the growth of the transplantable R3230 AC rat adenocarcinoma in Fischer 344 rats. This effect is dose-related; from the average three dosage levels studied, daily intake of 30 mg/kg rat/day was found to be optimal. However, Stadie slices of tumors from Tilorone-treated animals when transplanted, took, and showed a growth curve similar to tumors from untreated rats. Exposure to Tilorone does not select tumor cell clones of lesser malignancy or different histopathology.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D005449:Fluorenes / Q000627:therapeutic use*; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy; D051381:Rats; D011916:Rats, Inbred F344; D013994:Tilorone / Q000627:therapeutic use*; D014184:Transplantation, Homologous
D000970:Antineoplastic Agents; D005449:Fluorenes; D013994:Tilorone